The wide spectrum of those who filed briefs proves the enormity of support for the Affordable Care Act’s health insurance in general, and the continued availability of financial help for consumers (premium tax credits) in particular. Here’s a quick look at some of the individuals and groups who filed, along with the constituencies who would suffer if the Supreme Court rules in favor of withdrawing premium tax credits in states with federally facilitated marketplaces.
This advocacy agenda offers options for improving health and health care at the state level during the 2019 session. It includes state policy options to consider in 2019 regarding private insurance coverage, Medicaid, oral health coverage, health equity, prescription drugs, surprise medical bills, and health care value.
The Medicare Access and CHIP Reauthorization Act (MACRA) is the biggest change to how Medicare pays for services in decades. It will accelerate the movement towards value-based payments—where what health care providers get paid depends, at least partially, on the quality of care they provide, not just the volume of services. On June 27, Families USA submitted comments about how the law will be implemented.
As drug prices continue to rise at an unsustainable rate, we must ensure that our health care system and its financial incentives enhance the quality and value of care. We believe the Medicare Part B prescription drug model proposed by the Centers for Medicare & Medicaid Services (CMS) creates value for the patient and the program by encouraging treatment choices that have been shown to improve care and health outcomes.
Last Wednesday, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule to implement key provisions of the Medicare Access & CHIP Reauthorization Act. Passed with bipartisan support in 2015, MACRA represents is an important opportunity to improve the quality of care delivered through Medicare. Given the number of people who are enrolled in Medicare and the number of providers who see Medicare patients, these changes will have a significant impact throughout the entire health care system.
Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.
We know how the House Republican bill could affect people who get insurance through the Affordable Care Act (ACA) marketplace and Medicaid. But what has been overlooked is how the bill, known as the American Health Care Act (AHCA), could affect the coverage people get through their jobs. In other words: The Republican bill could make everybody’s coverage worse.
5:00 p.m. update—With three weeks until the end of open enrollment, one thing that distinguishes this period from last year’s is the lack of news. Things have been going pretty well.
Kevin Counihan of CMS noted that he’s grateful for the work of everyone at the conference: “This audience represents our salesforce.”
Counihan ran down the improvements CMS made to Healthcare.gov: reduced number of screens required to enroll from 76 down to 16, the site is warmer, fonts are bigger. “We’re learning.“
5:30 p.m.—We just heard from two leading thinkers in health policy debate some of the most pressing issues related to access to affordable health care in America.
In a wide-ranging discussion that covered everything from Medicaid policy to children’s benefits on the exchanges to the ACA’s subsidies, these two feisty policy wonks hashed out their visions for the future while reflecting on the past year.